Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Short Interest Report for October

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 11,020,929 shares, a decline of 48.2% from the October 15th total of 21,260,757 shares. Approximately 13.5% of the company’s shares are short sold. Based on an average daily volume of 29,799,680 shares, the days-to-cover ratio is currently 0.4 days.

Eyepoint Pharmaceuticals Trading Down 2.0%

Shares of EYPT stock traded down $0.01 during trading hours on Monday, hitting $0.30. 6,511,677 shares of the company were exchanged, compared to its average volume of 3,702,415. The business has a 50 day moving average of $2.33 and a two-hundred day moving average of $10.24. Eyepoint Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $19.11. The company has a market capitalization of $25.86 million, a PE ratio of -0.08 and a beta of 1.84.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.14). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.23 million. Eyepoint Pharmaceuticals had a negative net margin of 13,281.23% and a negative return on equity of 168.83%. On average, research analysts forecast that Eyepoint Pharmaceuticals will post -3.46 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on EYPT. Weiss Ratings lowered shares of Eyepoint Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. TD Cowen lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from $20.00 to $4.00 in a report on Wednesday, September 2nd. Guggenheim lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, October 19th. Laidlaw cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. downgraded Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, October 20th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $21.85.

View Our Latest Analysis on EYPT

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of EYPT. KBC Group NV acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter valued at approximately $29,000. Integrated Wealth Concepts LLC acquired a new position in Eyepoint Pharmaceuticals during the second quarter worth $72,000. Engineers Gate Manager LP acquired a new position in Eyepoint Pharmaceuticals during the second quarter worth $161,000. Levin Capital Strategies L.P. grew its position in Eyepoint Pharmaceuticals by 65.8% in the first quarter. Levin Capital Strategies L.P. now owns 31,500 shares of the company’s stock valued at $406,000 after purchasing an additional 12,500 shares in the last quarter. Finally, Baird Financial Group Inc. increased its stake in Eyepoint Pharmaceuticals by 16.4% in the 2nd quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock valued at $468,000 after buying an additional 4,613 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

About Eyepoint Pharmaceuticals

(Get Free Report)

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.

See Also

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.